Abstract:You have accessJournal of UrologyBladder Cancer: Upper Tract TCC I1 Apr 2015MP2-01 CONTRALATERAL UPPER TRACT UROTHELIAL CARCINOMA AFTER NEPHROURETERECTOMY: THE PREDICTIVE ROLE OF METHYLATION STATUS Lei Zhang, Gengyan Xiong, Dong Fang, Xuesong Li, Jin Liu, Weimin Ci, Wei Zhao, Nirmish Singla, Zhisong He, and Li Zhou Lei ZhangLei Zhang More articles by this author , Gengyan XiongGengyan Xiong More articles by this author , Dong FangDong Fang More articles by this author , Xuesong LiXuesong Li More articles by this author , Jin LiuJin Liu More articles by this author , Weimin CiWeimin Ci More articles by this author , Wei ZhaoWei Zhao More articles by this author , Nirmish SinglaNirmish Singla More articles by this author , Zhisong HeZhisong He More articles by this author , and Li ZhouLi Zhou More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.124AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Aberrant methylation of genes is one of the most common epigenetic modifications involved in the development of urothelial carcinoma. However, it is unknown that the predictive role of methylation to contralateral new upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). To evaluate the role of gene methylation in predicting contralateral UTUC recurrence after RNU. METHODS In a retrospective design, methylation of 10 genes was analyzed on tumor specimens belonging to 664 consecutive patients treated by RNU for primary UTUC. Median follow-up was 48 mo (range: 3–144 mo). Gene methylation was accessed by methylation-sensitive polymerase chain reaction, and we calculated the methylation index (MI), a reflection of the extent of methylation. The log-rank test and Cox regression were used to identify the predictor of contralateral UTUC recurrence. RESULTS Promoter methylation was present in 88.9% of UTUC. Fewer methylation and lower MI (P=0.001) were seen in the tumors with contralateral UTUC recurrence than the tumors without contralateral recurrence. High MI (P=0.007) was significantly correlated with poor cancer-specific survival. Multivariate analysis indicated that unmethylated RASSF1A (P=0.039), lack of bladder recurrence prior to contralateral UTUC (P=0.009), history of renal transplantation (P<0.001), and preoperative renal insufficiency (P=0.002) are independent risk factors for contralateral UTUC recurrence after RNU. CONCLUSIONS Methylation is frequent in UTUCs generally, and relative infrequent in tumors with contralateral UTUC recurrence. Methylation is a new promising predictor of contralateral UTUC recurrence after RNU. Table 3. MI based on the clinicopathological factors. No. of patients MI P Mean SD Grade <0.001* G1 21 0.1667 0.14606 G2 360 0.3161 0.22121 G3 283 0.3594 0.23732 Stage <0.001* Ta or T1 221 0.3009 0.21062 T2 237 0.2975 0.21803 T3 194 0.3964 0.24629 T4 12 0.4250 0.24541 N status 0.014* cN0 or pNo 617 0.3241 0.22860 N+ 47 0.4043 0.22259 Architecture 0.001* Papillary 515 0.3140 0.22534 Sessile 149 0.3846 0.23358 Ipsilateral hydronephrosis 0.015* Absence 290 0.3545 0.23248 Presence 374 0.3107 0.22461 Main tumor location 0.000* Pelvic 368 0.3677 0.23324 Upper ureter 58 0.2914 0.22027 Middle ureter 68 0.2824 0.21644 Lower ureter 170 0.2800 0.21334 Transplant recipient 0.011* No 653 0.3326 0.22861 Yes 11 0.1636 0.19117 MI=methylation index. Table 1. Patient demographic and histological data. Variables N (%) Gender Male 295 (44.4) Female 369 (55.6) Age <70 372 (56.0) ≥70 292 (44.0) Preoperative renal function eGFR≥60 298 (44.9) 60＞eGFR≥30 316 (47.6) eGFR＜30 50 (7.5) Side Left 326 (49.1) Right 338 (50.9) Transplant recipient No 653 (98.3) Yes 11 (1.7) Ipsilateral hydronephrosis Absence 290 (43.7) Presence 374 (56.3) Tobacco consumption No 543 (81.8) Yes 121 (18.2) Surgical approach Open 445 (67.0) Laparoscopic 219 (33.0) Tumor size ≤3cm 373 (56.2) ＞3cm 291 (43.8) Architecture Papillary 515 (77.6) Sessile 149 (22.4) Ureteroscopy No 583 (87.8) Yes 81 (12.2) Location Pelvis 368 (55.4) Ureter ureter 296 (44.6) Upper ureter 58 (8.7) Middle ureter 68 (10.2) Lower ureter 170 (25.6) Multifocality No 505 (76.1) Yes 159 (23.9) CIS Absence 645 (97.1) Presence 19 (2.9) Contralateral recurrence No 634 (95.5) Yes 30 (4.5) Bladder recurrence No 441 (66.4) Yes 223 (33.6) Before contralateral UTUC 209 (31.5) Concomitant and after contralateral UTUC 14 (2.1) Tumor stage Ta or T1 221 (33.3) T2 237 (35.7) T3 194 (29.2) T4 12 (1.8) Tumor grade G1 21 (3.2) G2 360 (54.2) G3 283 (42.6) N status N+ 47 (7.1) cN0 or pN0 617 (92.9) Adjuvant therapy No 641 (96.5) Yes 23 (3.5) eGFR=estimated glomerular filtration rate; CIS=carcinoma in situ; UTUC=upper tract urothelial carcinoma. Table 4. Predictive factors for contralateral UTUC recurrence after RNU Variable Univariate Multivariate Chi-square P HR 95% CI P Gender 2.051 0.152 Age 2.256 0.112 Renal function 27.746 <0.001* 0.418 0.242-0.723 0.002* Side 0.140 0.708 Transplant recipient 74.902 <0.001* 20.914 8.208-53.284 <0.001* Ipsilateral hydronephrosis 1.367 0.242 Smoke 0.063 0.802 Surgical approach 1.891 0.169 Tumor size 0.817 0.366 Architecture 0.737 0.391 Ureteroscopy 0.828 0.363 Location 2.015 0.569 Mulifocality 0.536 0.464 CIS 0.899 0.343 Bladder recurrencea 4.612 0.032* 0.258 0.097-0.691 0.007* Tumor stage 1.104 0.776 Tumor grade 1.730 0.421 N status 0.230 0.631 Adjuvant therapy 0.015 0.902 ABCC6 1.963 0.161 BRCA1 0.226 0.634 CDH1 2.226 0.136 GDF15 1.077 0.299 HSPA2 0.084 0.772 RASSF1A 5.481 0.019* 0.218 0.051-0.927 0.039* SALL3 1.696 0.193 THBS1 2.971 0.085 TMEFF2 1.072 0.301 VIM 5.004 0.025* 0.278 MI 3.918 0.048* -b CIS=carcinoma in situ; MI=methylation index. a Only bladder recurrence before contralateral UTUC recurrence was analyzed. b Because the MI correlated with methylation status of RASSF1A (r=0.412, P=0.000) and VIM (r=0.478, P=0.000), the MI was not analyzed in the multivariate models. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e9-e10 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lei Zhang More articles by this author Gengyan Xiong More articles by this author Dong Fang More articles by this author Xuesong Li More articles by this author Jin Liu More articles by this author Weimin Ci More articles by this author Wei Zhao More articles by this author Nirmish Singla More articles by this author Zhisong He More articles by this author Li Zhou More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...